Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27417839 | 0.84 | GABRA1 (0.42) | P2RX7NOTUMCTSSGABRA1GABRB2 | |
| SCHEMBL1043059 | 0.83 | P2RX7 (0.57) | P2RX7NOTUMCTSSCTSKPDK2 | |
| SCHEMBL22592568 | 0.83 | P2RX7 (0.38) | P2RX7NOTUMGABRA1GABRB2HSD11B1 | |
| SCHEMBL631113 | 0.79 | GABRA1 (0.40) | P2RX7GABRA1GABRB2PDK1PDK2 | |
| SCHEMBL9626847 | 0.79 | GABRA1 (0.56) | P2RX7GABRA1GABRB2PDK1PDK2 | |
| SCHEMBL8321560 | 0.79 | P2RX7 (0.41) | P2RX7NOTUMCTSSHSD11B1 | |
| SCHEMBL802989 | 0.77 | P2RX7 (0.53) | P2RX7NOTUMCTSSGABRA1GABRB2 | |
| SCHEMBL28985428 | 0.77 | GABRA1 (0.43) | P2RX7GABRA1GABRB2PDK1PDK2 | |
| SCHEMBL23374933 | 0.77 | PDK1 (0.44) | P2RX7CTSSGABRA1GABRB2CTSK | |
| SCHEMBL3821590 | 0.76 | TRPA1 (0.48) | P2RX7NOTUMCTSSGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | disclosed |
| WO-2022271562-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-3174877-B1 | INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2022-06-29 | — | — | EP | disclosed |
| CN-110078623-B | Method for preparing 2,2 '-bis (trifluoromethyl) -4, 4' -dinitrobiphenyl | 天津众泰材料科技有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2007017752-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-7157440-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060094739-A1 | 3-Aryl-3-hydroxy-2-methylenepropionic acid esters as fungicides | ATP CAPITAL LP | 2006-05-04 | — | — | US | disclosed |
| US-6946449-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| WO-2004007519-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030050275-A1 | Partial and full agonists of A1 adenosine receptors | GILEAD PALO ALTO, INC. | 2003-03-13 | — | — | US | disclosed |
| US-4532353-A | Substituted benzotrifluoride compounds as chemical intermediates and a process for their preparation | MONSANTO CO. (US) | 1985-07-30 | — | — | US | disclosed |
| EP-0008453-B1 | PROCESS FOR PREPARING TRIFLUOROMETHYL AROMATIC COMPOUNDS | BAYER AG (DE) | 1981-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | P2RX7 2906/4885NOTUM 4230/4885CTSS 3833/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | P2RX7 741/4885NOTUM 2644/4885CTSS 2228/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | P2RX7 874/4885NOTUM 4299/4885CTSS 1067/4885 |
| US-20030050275-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | P2RX7 38/4885NOTUM 3911/4885CTSS 3987/4885 |
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | P2RX7 387/4885NOTUM 2402/4885CTSS 3008/4885 |
| US-20230136562-A1 | SPIROUREA DERIVATIVES | KCNA7, PKD2, KCNN3 | P2RX7 81/4885NOTUM 4345/4885CTSS 3261/4885 |
| US-20060094739-A1 | 3-Aryl-3-hydroxy-2-methylenepropionic acid esters as fungicides | CYP51A1, DDT, CYP21A2 | P2RX7 2008/4885NOTUM 332/4885CTSS 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.